ArticleFrontiers in pediatrics2026
Retrospective evaluation of sirolimus (mTOR blocker) for lymphatic malformations presenting in the neonatal period: a single-center experience.
Article in Frontiers in pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lymphatic malformations are rare vascular anomalies. Currently, there is no uniform approach to the treatment of these patients. Neonates with extensive disease often suffer from multiple complications, organ dysfunction, and various tissue lesions, which may be life-threatening and lead to aesthetic deformity. Treatment with sirolimus has the potential to improve symptoms and downsize the lesion, up to complete regression. This retrospective single-center study presents our experience with oral sirolimus in the treatment of newborns with lymphatic malformations, evaluating its efficacy and safety. Methods: A retrospective analysis was conducted on 23 patients in the neonatal period and early infancy with lymphatic malformations, treated at the St. Petersburg State Pediatric Medical University between 2021 and 2025. Seven patients underwent primary radical surgical treatment and were not included in the analysis. The final study cohort consisted of 16 patients who received primary conservative therapy with sirolimus. Fifteen out of 16 patients started receiving oral sirolimus before the age of 28 days of life. The median age at the commencement of treatment was 15 days after birth. After instrumental and laboratory examination, sirolimus was administered at a starting reduced dose of 0.5 mg/m Results: Disease stabilization or regression was achieved in all 16 patients (100%), with a partial or complete radiological response (≥50% volume reduction) in 13 patients (81.25%) and complete regression (>90% volume reduction) in 10 patients (62.5%) at the 6-month assessment. No treatment-related serious adverse events requiring permanent discontinuation were observed. Recorded adverse events included transient respiratory infections ( Conclusion: In this selected cohort, sirolimus demonstrated an acceptable safety and efficacy profile, supporting its feasibility as a conservative first-line strategy in neonates with extensive or unresectable lymphatic malformations. However, larger prospective studies are needed to confirm these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.